PT - JOURNAL ARTICLE AU - Ssuuna, Charles AU - Galiwango, Ronald Moses AU - Kankaka, Edward Nelson AU - Kagaayi, Joseph AU - Ndyanabo, Anthony AU - Kigozi, Godfrey AU - Nakigozi, Gertrude AU - Lutalo, Tom AU - Ssekubugu, Robert AU - Wasswa, John Bosco AU - Mayinja, Anthony AU - Nakibuuka, Martina Cathy AU - Jamiru, Samiri AU - Oketch, John Baptist AU - Muwanga, Edward AU - Chang, Larry William AU - Grabowski, Mary Kate AU - Wawer, Maria AU - Gray, Ronald AU - Anderson, Mark AU - Stec, Michael AU - Cloherty, Gavin AU - Laeyendecker, Oliver AU - Reynolds, Steven James AU - Quinn, Thomas C. AU - Serwadda, David TI - Severe Acute Respiratory Syndrome Coronavirus-2 seropositivity in South-Central Uganda, during 2019 - 2021 AID - 10.1101/2021.09.13.21263414 DP - 2021 Jan 01 TA - medRxiv PG - 2021.09.13.21263414 4099 - http://medrxiv.org/content/early/2021/09/16/2021.09.13.21263414.short 4100 - http://medrxiv.org/content/early/2021/09/16/2021.09.13.21263414.full AB - Globally, key subpopulations have a high risk of contracting SARS-CoV-2. In Uganda, limited access to personal protective equipment amidst lack of clarity on the extent of the community disease burden may exacerbate this situation.We assessed SARS-CoV-2 antibody seroprevalence among high-risk sub-populations, including healthcare workers, persons within the general population previously reporting experiencing key COVID-19 like symptoms and archived plasma specimens collected prior to confirmation of COVID-19 in Uganda.We collected venous blood from HCWs at selected health facilities and from population-cohort participants who reported specific COVID-19 like symptoms in a prior phone-based survey conducted during the first national lockdown (May-August 2020). Pre-lockdown plasma collected from individuals considered high risk for SARS-CoV-2 infection was retrieved. Specimens were tested for antibodies to SARS-CoV-2 using the CoronaChek™ rapid COVID-19 IgM/IgG lateral flow test assay. IgM only positive samples were confirmed using a chemiluminescent microparticle immunoassay (ARCHITECT AdviseDx SARS-CoV-2 IgM) which targets the spike. SARS-CoV-2 exposure was defined as either confirmed IgM, both IgM and IgG or sole IgG positivity.The seroprevalence of antibodies to SARS-CoV-2 in HCWs was 21.1% [95%CI: 18.2-24.2]. Of the phone-based survey participants, 11.9% [95%CI: 8.0-16.8] had antibodies to SARS-CoV-2. Among 636 pre-lockdown plasma specimens, 1.7% [95%CI: 0.9-3.1] were reactive.Findings suggest a high seroprevalence of antibodies to SARS-CoV-2 among HCWs and substantial exposure in persons presenting with specific COVID-19 like symptoms in the general population of South-central Uganda. Based on current limitations in serological test confirmation, it remains unclear whether pre-lockdown seropositivity implies prior SARS-CoV-2 exposure in Uganda.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was funded by the Government of Uganda through Makerere University Research and Innovations Fund (Grant number RIF/COVID/075, https://rif.mak.ac.ug/ ) and in part by the Division of Intramural Research, National Institute of Allergy, and Infectious Diseases (NIH, https://www.niaid.nih.gov/about/dir ). The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Uganda Virus Research Institute Research Ethics Committee (Ref. GC/127/20/08/785), registered, and cleared by the Uganda National Council for Science and Technology (UNCST) (registration number HS878ES)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data has been provided in the manuscript.